Celcuity Inc. announced a delay in the commercial launch of its FDA-approved breast cancer therapy Revtorpyk, now expected in late Q3 2026, later than analysts anticipated. This unexpected delay caused Celcuity's stock to fall over 17%, prompting an investigation by law firm Kessler Topaz Meltzer & Check LLP into potential securities law violations. Investors who suffered losses from Celcuity securities may have legal rights to pursue claims. The law firm encourages affected investors to contact them for legal assistance.
The latest episode of Troutman Amin, LLP's Deserve to Win Podcast features interviews with CEOs from Contact Center Compliance, PureCaller ID, and Sonera, discussing the merger of CCC and PCID into Sonera and its impact on telecom industry consolidat...
Pepeto's crypto presale is rapidly selling out, raising over $10.398 million despite a challenging market, signaling strong investor interest. This surge coincides with Solana's price recovery to $81 and optimistic forecasts of $500 in 2026, highligh...
James Altucher projects that Elon Musk's humanoid robot, dubbed "A.R.M.," could surpass Amazon's $600 billion annual revenue by producing up to 10 million units yearly. Priced between $20,000 and $30,000 each, initial production of 1 million robots c...
Silicon Labs introduced the BG2B, a new Bluetooth 6 low energy SoC designed for smaller, more secure, and longer-lasting IoT devices. The BG2B offers the industry's lowest power consumption with advanced features like Channel Sounding for location aw...
Roblox has reduced its guided bookings forecast by as much as 18% and withdrawn its full-year financial outlook. This adjustment is linked to a deliberate change in the platform's algorithm, which has impacted user engagement and revenue projections....
